Nature Communications (Jun 2024)
Generation of nanobodies from transgenic ‘LamaMice’ lacking an endogenous immunoglobulin repertoire
- Thomas Eden,
- Alessa Z. Schaffrath,
- Janusz Wesolowski,
- Tobias Stähler,
- Natalie Tode,
- Nathalie Richter,
- Waldemar Schäfer,
- Julia Hambach,
- Irm Hermans-Borgmeyer,
- Jannis Woens,
- Camille M. Le Gall,
- Sabrina Wendler,
- Christian Linke-Winnebeck,
- Martina Stobbe,
- Iwona Budnicki,
- Amelie Wanney,
- Yannic Heitz,
- Lena Schimmelpfennig,
- Laura Schweitzer,
- Dennis Zimmer,
- Erik Stahl,
- Fabienne Seyfried,
- Anna J. Gebhardt,
- Lynn Dieckow,
- Kristoffer Riecken,
- Boris Fehse,
- Peter Bannas,
- Tim Magnus,
- Martijn Verdoes,
- Carl G. Figdor,
- Klaus F. Hartlepp,
- Hubertus Schleer,
- Jonas Füner,
- Nicola M. Tomas,
- Friedrich Haag,
- Björn Rissiek,
- Anna M. Mann,
- Stephan Menzel,
- Friedrich Koch-Nolte
Affiliations
- Thomas Eden
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Alessa Z. Schaffrath
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Janusz Wesolowski
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Tobias Stähler
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Natalie Tode
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Nathalie Richter
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Waldemar Schäfer
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Julia Hambach
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Irm Hermans-Borgmeyer
- Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf
- Jannis Woens
- Research Department Cell and Gene Therapy, University Medical Center Hamburg-Eppendorf
- Camille M. Le Gall
- Department of Medical BioSciences, Radboud University Medical Center
- Sabrina Wendler
- ChromoTek GmbH, Martinsried, Germany - A part of Proteintech Group
- Christian Linke-Winnebeck
- ChromoTek GmbH, Martinsried, Germany - A part of Proteintech Group
- Martina Stobbe
- ChromoTek GmbH, Martinsried, Germany - A part of Proteintech Group
- Iwona Budnicki
- Genovac GmbH
- Amelie Wanney
- Genovac GmbH
- Yannic Heitz
- Genovac GmbH
- Lena Schimmelpfennig
- Genovac GmbH
- Laura Schweitzer
- Genovac GmbH
- Dennis Zimmer
- Genovac GmbH
- Erik Stahl
- Preclinics GmbH
- Fabienne Seyfried
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Anna J. Gebhardt
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Lynn Dieckow
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Kristoffer Riecken
- Research Department Cell and Gene Therapy, University Medical Center Hamburg-Eppendorf
- Boris Fehse
- Research Department Cell and Gene Therapy, University Medical Center Hamburg-Eppendorf
- Peter Bannas
- Department of Radiology, University Medical Center Hamburg-Eppendorf
- Tim Magnus
- Department of Neurology, University Medical Center Hamburg-Eppendorf
- Martijn Verdoes
- Department of Medical BioSciences, Radboud University Medical Center
- Carl G. Figdor
- Department of Medical BioSciences, Radboud University Medical Center
- Klaus F. Hartlepp
- ChromoTek GmbH, Martinsried, Germany - A part of Proteintech Group
- Hubertus Schleer
- Genovac GmbH
- Jonas Füner
- Preclinics GmbH
- Nicola M. Tomas
- III. Department of Medicine, University Medical Center Hamburg-Eppendorf
- Friedrich Haag
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Björn Rissiek
- Department of Neurology, University Medical Center Hamburg-Eppendorf
- Anna M. Mann
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Stephan Menzel
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- Friedrich Koch-Nolte
- Institute of Immunology, University Medical Center Hamburg-Eppendorf
- DOI
- https://doi.org/10.1038/s41467-024-48735-x
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 14
Abstract
Abstract Due to their exceptional solubility and stability, nanobodies have emerged as powerful building blocks for research tools and therapeutics. However, their generation in llamas is cumbersome and costly. Here, by inserting an engineered llama immunoglobulin heavy chain (IgH) locus into IgH-deficient mice, we generate a transgenic mouse line, which we refer to as ‘LamaMouse’. We demonstrate that LamaMice solely express llama IgH molecules without association to Igκ or λ light chains. Immunization of LamaMice with AAV8, the receptor-binding domain of the SARS-CoV-2 spike protein, IgE, IgG2c, and CLEC9A enabled us to readily select respective target-specific nanobodies using classical hybridoma and phage display technologies, single B cell screening, and direct cloning of the nanobody-repertoire into a mammalian expression vector. Our work shows that the LamaMouse represents a flexible and broadly applicable platform for a facilitated selection of target-specific nanobodies.